Your current position:HOME > Products & Services > Tumor Gene Detection > GIST
Products & Services
Summary of GIST
GIST, namely gastrointestinal stromal tumor, is the most common gastrointestinal mesenchymal tumor of gastrointestinal tract, GIST originates from any part of the gastrointestinal tract, of which stomach(60%) and small intestine (30%) are the most common primary site. According to the latest statistic data, there are about 18,000 new cases of GIST per year in China.

Scientific studies have verified that cancer is caused by the genetic mutation of human body; genetic mutation can lead to infinite proliferation of cells due to losing of normal control ability, eventually resulting in occurrence of cancer. While the targeted drugs can kill the tumor cells carrying specific gene variations, with apparent curative effects, therefore, it is regarded as a first choice for advanced cancer patients in multiple cancer types. Presently, Imatinib, Sunitinib, Regorafenib and so on have been approved by FDA/CFDA. But, the gene variations carried by different patients are different, which makes patients with different sensitivity, toxic and adverse effects for same antineoplastic drugs.

The precision diagnosis is a prerequisite for accurate medication. The idea of molecular genotype makes the doctors formulate best therapeutic regimen according to biomarkers carried by GIST patients and corresponding clinical status, to greatly find out potentially available targeted drugs and enhance treatment efficiency of antineoplastic drugs.

  The occurrence of tumors is often accompanied by multiple gene variations and heterogeneity. The second generation sequencing technology can realize parallel detection on multiple genes, saving samples compared to traditional detection methods and reaching higher technology sensitivity, to restore tumor mutation in a more real manner.
GIST core™

Genes covered in GIST core™


Targeted drugs covered in GIST core™


Gene detection of individualized medication of gastrointestinal stromal tumor

Burning Rock GIST core™, targeted at patients with GIST, by applying the advanced second sequencing technique, can comprehensively detect the drug-inhibited target genes related to GIST, which clinically provides reference information of selection of individualized treatment for GIST.

More comprehensive individualized medication choice:

GIST core™ comprehensively detects the drug-inhibited target genes suggested in gastrointestinal stromal tumor NCCN guideline, drug-inhibited target spot researched in phase Ⅱ/Ⅲclinical trial of gastrointestinal stromal tumor and approved drug-inhibited target spot in all kinds of cancers, provides the most comprehensive individualized medication genetic detecting of gastrointestinal stromal tumor.

More accurate gene mutation detection related to GIST:

The gene detection Panel based on the second generation sequencing technology optimized by Burning Rock Dx, can detect 4 types of variation types at one time (mutation, insertion and deletion, fusion, amplification, etc.), at the same time, applies deep sequencing to deeply cover trace genovariation, so as to provide full view of the precise genovariation although samples are limited. On the one hand, the parallel detecting with the polygenic high sensitivity  improves the detection rate of drug-inhibited genovariation, which is able to miss opportunity of dedication; On the other hand, the complete coverage of exons can detect the hot spots and rare even unknown genovariation at the same time in one detection, detect related drug-resistant mutation while discovering drug sensitivity mutation,  having an accurate reflection of the sensitivity and drug resistance information of the patients after the usage of medication.

More professional detection report interpretation:

Buring Rock Dx, having the patented automated analysis system, is also the domestic third party detecting company only owning the professional medical department. The improved software and hardware resources ensures the accuracy of every detection report, which provides accurate and comprehensive basis of designing more reasonable individualized treatment scheme for doctors.

Applicable Populations


Sample Requirements

Operation organization and biopsy samples, fresh tissues or paraffin embedding samples are available.

Service Cycle

After sample inspection, detailed detection report will be issued in 10 natural days.

Service Procedure

Cases Sharing